Patents Examined by D. Margaret Seaman
  • Patent number: 8058442
    Abstract: Novel iron chelators exhibiting neuroprotective and good transport properties are useful in iron chelation therapy for treatment of a disease, disorder or condition associated with iron overload and oxidative stress, eg. a neurodegenerative or cerebrovascular disease or disorder, a neoplastic disease, hemochromatosis, thalassemia, a cardiovascular disease, diabetes, a inflammatory disorder, anthracycline cardiotoxicity, a viral infection, a protozoal infection, a yeast infection, retarding ageing, and prevention and/or treatment of skin ageing and skin protection against sunlight and/or UV light. The iron chelator function is provided by a 8-hydroxyquinoline, a hydroxypyridinone or a hydroxamate moiety, the neuroprotective function is imparted to the compound e.g. by a neuroprotective peptide, and a combined antiapoptotic and neuroprotective function by a propargyl group.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: November 15, 2011
    Assignees: Technion Research and Development Foundation Ltd., Yeda Research and Development Co., Ltd.
    Inventors: Moussa Youdim, Matitiyahu Fridkin, Hailin Zheng, Abraham Warshawsky, Rivka Warshawsky, legal representative
  • Patent number: 8012992
    Abstract: The present invention provides compounds are disclosed herein having the formula: Wherein n is 1 or 2; m is 0 or 1; p is 0, 1 or 2; R1 is aryl, heteroaryl or alkyl; R2 is C1-6 hydrocarbyl, alkylacyl or hydroxyalkyl; R3 is aryl, heteroaryl, or alkyl; R4 is H, OH, —O—(C1-6 alkyl), —NH—(C1-6 alkyl), or oxide; R5 is H, halogen, C1-6 alkyl, O—(C1-6 alkyl), aryl, heteroaryl, —C(?O)(C1-6 alkyl), substituted or un-substituted oxazolin-2-yl; X?O, NH, —C(?O)— or —N?CH—; and Each L is independently alkylene and carbonyl. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
    Type: Grant
    Filed: June 29, 2009
    Date of Patent: September 6, 2011
    Assignee: Allergan, Inc.
    Inventor: Haiqing Yuan
  • Patent number: 7994194
    Abstract: This invention relates to novel compounds that are 4-oxoquinoline derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel 4-oxoquinoline derivatives that are derivatives of elvitegravir. This invention also provides pyrogen-free compositions comprising one or more compounds of this invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an HIV integrase inhibitor, such as elvitegravir.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: August 9, 2011
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson
  • Patent number: 7985860
    Abstract: This application discloses a novel process to synthesize 2-(Quinolin-5yo)-4,5-Disubstituted-Azole derivatives, which may be used, for example, as PDE IV inhibitor compounds in pharmaceutical preparations.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: July 26, 2011
    Assignee: Schering Corporation
    Inventors: Timothy D. Cutarelli, Xiaoyong Fu, Timothy L. McAllister, Michael R. Reeder, Jianguo Yin, Kelvin H. Yong, Shuyi Zhang
  • Patent number: 7982043
    Abstract: This invention provides compounds of formula 1, having the structure wherein R1, R2, R3, R4, and R5 are described within the specification.
    Type: Grant
    Filed: June 10, 2008
    Date of Patent: July 19, 2011
    Assignee: Wyeth LLC
    Inventors: Allan Wissner, Sridhar Krishna Rabindran, Hwei-Ru Tsou
  • Patent number: 7977350
    Abstract: The invention provides compounds having the formula: wherein R1 is halogen. The invention also provides compositions comprising the compounds, and methods of treating diseases or disorders that comprise administering one or more of the compounds to a subject in need thereof. The disclosed compounds have CCR1 antagonist activity.
    Type: Grant
    Filed: April 22, 2010
    Date of Patent: July 12, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth G. Carson, Geraldine C. B. Harriman, Shomir Ghosh
  • Patent number: 7973164
    Abstract: The invention concerns quinoline derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: March 1, 2007
    Date of Patent: July 5, 2011
    Assignee: AstraZeneca AB
    Inventors: Frederic Henri Jung, Patrick Ple
  • Patent number: 7968563
    Abstract: Imidazo[4,5-c] ring compounds, (e.g. imidazo[4,5-c]pyridines, imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydro imidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridine, and 6,7,8,9-tetrahydro imidazo[4,5-c]naphthyridine compounds) having an oxime or hydroxylamine substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.
    Type: Grant
    Filed: February 10, 2006
    Date of Patent: June 28, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Tushar A. Kshirsagar, Gregory D. Lundquist, Jr., Joseph F. Dellaria, Matthew R. Radmer, Bernhard M. Zimmermann
  • Patent number: 7968566
    Abstract: Novel compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R, R1, R2, R3, R4, R5, and R6 have the meanings given in the description, pharmaceutical compositions comprising said compounds and use thereof as protein kinase inhibitors.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: June 28, 2011
    Assignee: Aventis Pharma S.A.
    Inventors: Sylvie Wentzler, Youssef El-Ahmad, Bruno Filoche-Romme, Conception Nemecek, Corinne Venot, Augustin Hittinger
  • Patent number: 7964731
    Abstract: The invention relates to adenozin A3 receptor ligands labeled with iodine isotops of mass number 125, within those favorably to antagonists and their isomers, to the experimental materials containing them, to a process for the preparation of the compounds of the general formula (I) and their isomers, to the new intermediates of the general formula (II) and to the preparation thereof.
    Type: Grant
    Filed: May 14, 2007
    Date of Patent: June 21, 2011
    Assignee: Sanofi-Aventis
    Inventors: Geza Timari, Kinga Boer, Geza Toth, Csaba Tomboly
  • Patent number: 7964616
    Abstract: The invention provides compounds of formula (I), processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy, wherein R1, R2, R3 and n are as defined in the specification
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: June 21, 2011
    Assignee: AstraZeneca AB
    Inventors: Mark Ebden, Simon David Guile
  • Patent number: 7964730
    Abstract: The invention provides novel ?2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with ?2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: June 21, 2011
    Assignee: Theravance, Inc.
    Inventors: Martin S. Linsell, John R. Jacobsen, Daisuke Roland Saito
  • Patent number: 7964733
    Abstract: Compounds of Formula I wherein R1, A, R2, R3, R4, R5, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Grant
    Filed: September 19, 2006
    Date of Patent: June 21, 2011
    Assignee: AstraZeneca AB
    Inventors: Jeffrey S. Albert, Gerard M. Koether, Cristobal Alhambra, James Kang, Thomas R. Simpson, James Woods, Yan Li
  • Patent number: 7960551
    Abstract: A succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-5-methoxyphenylcarbamoyl)ethyl]piperidin-4-yl ester or a solvate thereof, for use in treating pulmonary disorders.
    Type: Grant
    Filed: February 8, 2007
    Date of Patent: June 14, 2011
    Assignee: Glaxo Group Limited
    Inventors: Reshma Chudasama, Andrew Kennedy
  • Patent number: 7960408
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR?. In particular, the compounds of the invention modulate the function of PPAR?. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: June 14, 2011
    Assignee: Amgen Inc.
    Inventors: Lawrence R. McGee, Jonathan B. Houze, Steven M. Rubenstein, Atsushi Hagiwara, Noboru Furukawa, Hisashi Shinkai
  • Patent number: 7956188
    Abstract: Compounds of the general formula (I); wherein the substituents are as defined in claim 1, are useful as fungicides.
    Type: Grant
    Filed: November 29, 2005
    Date of Patent: June 7, 2011
    Assignee: Syngenta Crop Protection, Inc.
    Inventors: Roger Salmon, David Philip Bacon, Ewan James Turner Chrystal, David William Langton, Andrew Jonathan Knee, Gordon Richard Munns, Laura Quaranta, Hans-Georg Brunner, Renaud Beaudegnies, Fredrik Cederbaum, Fiona Murphy Kessabi
  • Patent number: 7956189
    Abstract: Disclosed are maleate, tosylate, fumarate, and oxalate salts of the compound 5-(1(S)-Amino-2-Hydroxyethyl)-N-[(2,4-Difluorophenyl)-Methyl]-2-[8-Methoxy-2-(Trifluoromethyl)-5-Quinoline]-4-Oxazolecarboxamide, represented by Formula I, and methods of preparing the same.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: June 7, 2011
    Assignee: Schering Corporation
    Inventors: Xiaoming Chen, Xiao Chen, Jianguo Yin, Xiaoyong Fu, David J. Blythin, Rongze Kuang, Ho-Jane Shue, Scott Trzaska, Chee-Wah Tang, Vincenzo Liotta, Zaher Shabani
  • Patent number: 7951950
    Abstract: Disclosed are CRTH2 inhibitors represented by Structural Formula (I): The values for the variables of Structural Formula (I) are provided herein.
    Type: Grant
    Filed: February 23, 2006
    Date of Patent: May 31, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Jeremy D. Little, Shomir Ghosh, Sean Harrison, Amy M. Elder, Christelle C. Renou, Kenneth G. Carson
  • Patent number: 7947710
    Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: August 26, 2008
    Date of Patent: May 24, 2011
    Assignee: Theravance, Inc.
    Inventors: Daisuke Roland Saito, Daniel D. Long, John R. Jacobsen
  • Patent number: 7947706
    Abstract: The invention relates to compounds of formula (I): wherein Ra, R1, Ar, L, A, W, Y, and Z are as defined in the disclosure; to compositions containing them; and to the preparation and use thereof, in particular as anticancer agents.
    Type: Grant
    Filed: October 11, 2007
    Date of Patent: May 24, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Michel Tabart, Eric Bacque, Frank Halley, Baptiste Ronan, Pascal Desmazeau, Fabrice Viviani, Catherine Souaille